Virtus ETF Advisers’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,415
| Closed | -$66.6K | – | 522 |
|
|
2024
Q4 | $66.6K | Sell |
1,415
-332
| -19% | -$17.2K | 0.03% | 407 |
|
|
2024
Q3 | $92.2K | Buy |
1,747
+30
| +2% | +$1.67K | 0.04% | 387 |
|
|
2024
Q2 | $93K | Sell |
1,717
-650
| -27% | -$39.2K | 0.05% | 344 |
|
|
2024
Q1 | $166K | Sell |
2,367
-162
| -6% | -$12.5K | 0.09% | 311 |
|
|
2023
Q4 | $211K | Sell |
2,529
-295
| -10% | -$10.7K | 0.13% | 282 |
|
|
2023
Q3 | $83.2K | Sell |
2,824
-282
| -9% | -$9.39K | 0.05% | 352 |
|
|
2023
Q2 | $101K | Buy |
3,106
+661
| +27% | +$24.5K | 0.06% | 373 |
|
|
2023
Q1 | $86K | Sell |
2,445
-938
| -28% | -$38.3K | 0.05% | 375 |
|
|
2022
Q4 | $155K | Buy |
3,383
+718
| +27% | +$30.9K | 0.08% | 337 |
|
|
2022
Q3 | $129K | Buy |
2,665
+18
| +0.7% | +$866 | 0.05% | 380 |
|
|
2022
Q2 | $104K | Sell |
2,647
-1,529
| -37% | -$61.6K | 0.04% | 423 |
|
|
2022
Q1 | $154K | Sell |
4,176
-249
| -6% | -$8.85K | 0.07% | 224 |
|
|
2021
Q4 | $202K | Sell |
4,425
-5,298
| -54% | -$204K | 0.08% | 204 |
|
|
2021
Q3 | $348K | Sell |
9,723
-514
| -5% | -$15.1K | 0.15% | 185 |
|
|
2021
Q2 | $203K | Sell |
10,237
-3,899
| -28% | -$91.5K | 0.08% | 334 |
|
|
2021
Q1 | $329K | Buy |
14,136
+247
| +2% | +$5.27K | 0.14% | 223 |
|
|
2020
Q4 | $289K | Sell |
13,889
-528
| -4% | -$9.65K | 0.12% | 229 |
|
|
2020
Q3 | $312K | Sell |
14,417
-1,971
| -12% | -$46.1K | 0.16% | 211 |
|
|
2020
Q2 | $386K | Sell |
16,388
-17,366
| -51% | -$326K | 0.18% | 213 |
|
|
2020
Q1 | $398K | Sell |
33,754
-4,932
| -13% | -$62.9K | 0.16% | 198 |
|
|
2019
Q4 | $410K | Buy |
38,686
+12,199
| +46% | +$125K | 0.07% | 245 |
|
|
2019
Q3 | $301K | Sell |
26,487
-1,475
| -5% | -$18.5K | 0.06% | 199 |
|
|
2019
Q2 | $315K | Sell |
27,962
-5,796
| -17% | -$55.9K | 0.07% | 202 |
|
|
2019
Q1 | $273K | Sell |
33,758
-3,729
| -10% | -$27.4K | 0.58% | 67 |
|
|
2018
Q4 | $237K | Sell |
37,487
-12,590
| -25% | -$92.4K | 0.04% | 167 |
|
|
2018
Q3 | $493K | Sell |
50,077
-35,803
| -42% | -$287K | 0.05% | 127 |
|
|
2018
Q2 | $713K | Sell |
85,880
-7,429
| -8% | -$61.8K | 0.63% | 96 |
|
|
2018
Q1 | $672K | Buy |
93,309
+50,664
| +119% | +$434K | 0.58% | 97 |
|
|
2017
Q4 | $348K | Buy |
42,645
+19,250
| +82% | +$219K | 0.44% | 93 |
|
|
2017
Q3 | $339K | Buy |
23,395
+2,140
| +10% | +$29.2K | 0.05% | 125 |
|
|
2017
Q2 | $257K | Sell |
21,255
-3,624
| -15% | -$50.4K | 0.04% | 141 |
|
|
2017
Q1 | $320K | Buy |
24,879
+2,385
| +11% | +$27.9K | 0.06% | 130 |
|
|
2016
Q4 | $273K | Sell |
22,494
-6,885
| -23% | -$73.1K | 0.08% | 118 |
|
|
2016
Q3 | $270K | Hold |
29,379
| – | – | 0.13% | 111 |
|
|
2016
Q2 | $279K | Buy |
29,379
+7,255
| +33% | +$59.5K | 0.21% | 68 |
|
|
2016
Q1 | $156K | Buy |
+22,124
| New | +$162K | 0.21% | 116 |
|
Other funds holding CYTK
DTC
RI
Virtus ETF Advisers's CYTK Position: Q1 2025 in Review
Virtus ETF Advisers sold out of Cytokinetics (CYTK) in Q1 2025, closing a stake of 1,415 shares — an estimated $66.6K sold.
Virtus ETF Advisers first reported a position in CYTK in Q1 2016 and held it in 36 quarters. The position peaked at $713K in Q2 2018. 355 funds tracked by Wall St. Rank hold CYTK as of Q1 2025.
- Virtus ETF Advisers reported no remaining Cytokinetics position as of Q1 2025 after selling out during the quarter.
- Virtus ETF Advisers sold 1,415 Cytokinetics shares in Q1 2025, an estimated $66.6K.
- Virtus ETF Advisers first reported a position in Cytokinetics in Q1 2016 and held it in 36 quarters.
- Virtus ETF Advisers's Cytokinetics position peaked at $713K in Q2 2018.
- 355 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2025.
Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.